

**NAVANA PHARMA****NAVANA PHARMACEUTICALS PLC.**Corporate Office : House # 99, Road # 04, Block # B,
Banani, Dhaka -1213**PRICE SENSITIVE INFORMATION**

This is for kind information to all valued shareholders of Navana Pharmaceuticals PLC. and stakeholders that the Board of Directors of the company in its 51st meeting held on January 29, 2025 ended at 4.00 p.m. has considered and approved, among others, the Un-audited Financial Statements for the Second quarter (Q2) period ended on December 31, 2024 and took the following Price Sensitive Decision:-

Comparative Statement on Un-audited Financial Statement for the Second quarter (Q2, FY-2024-2025) period ended on December 31, 2024:

Sl. No	Particulars	01.07.2024-31.12.2024	01.07.2023-31.12.2023	01.10.2024-31.12.2024	01.10.2023-31.12.2023
I	Net Profit After Tax	241,444,123	224,318,207	107,694,911	104,768,117
II	Earnings Per Share (EPS)	2.25	2.09	1.00	0.98
III	Net Operating Cash Flow Per Share (NOCFPS)	3.16	0.87	N/A	N/A
		As on 31.12.2024	As On 30.06.2024		
IV	Net Asset Value (NAV)	4,736,555,804	4,561,095,560	N/A	N/A
V	Net Asset Value Per Share	44.10	42.46	N/A	N/A

Notes:**● Reasons of significant deviation in Net Operating Cash Flow Per Share (NOCFPS) between the quarterly periods:**

- **NOCFPS:** Net Operating Cash Flow per Share (NOCFPS) has increased to Tk. 3.16 from Tk.0.87, due to cash received from the customers was higher than the cash payment to the vendors in the reporting period.

- In compliance with the Dhaka & Chittagong Stock Exchange (Listing) Regulation, 2015, the company is pleased to publish the Un-audited Financial Statement for the Second quarter (Q2) period ended on December 31, 2024 in two widely circulated daily newspapers (one in Bengali and other one in English) and also in an online news portal. The detail of the published quarterly Financial Statements will be available in the website (www.navanapharma.com) of the company.

Dated: January 29, 2025

By order of the Board
Sd/-**Lorens Shamol Mollick FCS**
Company Secretary